Techniques: Guidelines

Imaging

EANM-SNMMI Practice Guideline for Tele-Nuclear Medicine 2.0 (2013)

Tele-nuclear medicine may improve health care by allowing for more timely interpretation and by facilitating consultation.

SNM/EANM Guideline for Guideline Development 6.0 (2012)

The purpose of this guideline is to describe an explicit, well-documented methodology for the development of guidelines in the field of nuclear medicine. The process necessary for approval of a guideline is also described. The same process is applicable for approval of SNM- or EANM-only guidelines and collaborative guidelines. For SNM-only guidelines, the EANM committees and executive committee do not need to review and approve the guideline. For EANMonly guidelines, the SNM committees and SNM Board of Directors do not need to review and approve the guideline.

(SNM) General Imaging 6.0 (2010)

The purpose of this document is to provide nuclear medicine practitioners with general guidelines on imaging in the practice of nuclear medicine. The guideline includes recommendations common to most nuclear medicine imaging procedures. Nuclear medicine is the medical specialty that uses the tracer principle, most often with radiopharmaceuticals, to evaluate molecular, metabolic, physiologic and pathologic conditions of the body for the purposes of diagnosis, therapy and research. The combination of anatomic information from other modalities may complement the information from tracers providing more information than the sum of the two separately.

EANM procedure guidelines for FDG PET and PET/CT tumour imaging (2009)

The aim of this guideline is to provide a minimum standard for the acquisition and interpretation of PET and PET/CT scans with [18F]-fluorodeoxyglucose (FDG).The Procedure Guidelines for Tumour Imaging with FDG PET/CT of the Society of Nuclear Medicine (SNM), the German Guidelines for FDG-PET/CT in Oncology, the quality control/assurance procedures used in the UK for lymphoma/head and neck cancer studies and the Netherlands protocol for standardisation of quantitative whole-body FDG PET/CT studies have been integrated in the present guideline.

EANM Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology (2008)

The purpose of these guidelines is to offer to the nuclear medicine team a framework that could prove helpful in daily practice. These guidelines contain information related to the indications, acquisition, processing and interpretation of ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG PET) in paediatric oncology.

(SNM) Recommendations on the use of 18F-FDG PET in oncology (2008)

The purpose of this guideline is to develop recommendations on the use of (18)F-FDG PET in breast, colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma, melanoma, and sarcoma; and unknown primary tumor. Outcomes of interest included the use of (18)F-FDG PET for diagnosing, staging, and detecting the recurrence or progression of cancer.

(SNM) Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT 1.0 (2006)

The purpose of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of 18-fluoro-2-deoxyglucose (FDG) imaging in the evaluation of patients with suspected malignant disease, in adult and pediatric patients, for the staging of malignant disease, or for the monitoring of therapy.

SNM Procedure Guideline for SPECT/CT Imaging (2006)

The purpose of this Procedure Guideline is to assist physicians in recommending, performing, interpreting, and reporting the results of SPECT/CT for imaging of adult and pediatric patients. Although techniques for registration and fusion of images obtained from separate SPECT and CT scanners have been available for several years, the advantages of having SPECT and CT integrated into a single device have resulted in the development of this technology in the United States and elsewhere in the world. This Procedure Guideline pertains only to combined SPECT/CT devices.

This standard was revised collaboratively by the American College of Radiology (ACR) and the Society of Nuclear Medicine (SNM). This standard was developed to cover key aspects pertinent to the performance of nuclear imaging and in-vivo nonimaging diagnostic studies using radio-pharmaceuticals.

Guidelines on current good Radiopharmacy Practice (cGRPP) for the small-scale preparations of radiopharmaceuticals (2010)

Guidelines on current good Radiopharmacy Practice (cGRPP) in the Preparation of Radiopharmaceuticals (2007)

Use of Radiopharmaceuticals 4.0 (2004)

This guideline was developed by the SNM to describe important factors common to most nuclear medicine procedures. It is intended to guide nuclear medicine practitioners in establishing policies and procedures for the use of radiopharmaceuticals in clinical practice. This guideline is intended to be concordant with the regulations of the Nuclear Regulatory Commission and other state and federal government agencies.